Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial
Resumen
Palabras clave
HER2 negativo; Ipatasertib; PI3K/AKT
Citación recomendada
Turner N, Dent RA, O'Shaughnessy J, Kim SB, Isakoff SJ, Barrios C, et al. Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. Breast Cancer Res Treat. 2022 Feb;191:565–576.
Audiencia
Professionals
Usar este identificador para citar y/o enlazar este documento
https://hdl.handle.net/11351/7661Este elemento aparece en las siguientes colecciones
- HVH - Articles científics [2949]
- VHIO - Articles científics [860]
El ítem tiene asociados los siguientes ficheros de licencia: